-
CStone Pharmaceuticals announced that the clinical trial application of lolatinib for ROS1-positive advanced non-small cell lung cancer in China has been accepted by the China National Medical Products Administration
Time of Update: 2021-11-04
Suzhou, China, October 20, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, It was announced today that the clinical trial application (IND) of lorlatinib (lorlatinib, formerly known as loratinib) for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been accepted by the National Medical Products Administration (NMPA) of China .
-
Analysis of the layout of Chinese innovative drugs at home and abroad: Do not all innovative drugs have a future?
Time of Update: 2021-11-04
Analysis of the overall situation of China's pharmaceutical industryOn October 8, 2021, Evive Biotech, a holding subsidiary of Evive Biotech, announced that the European Medicines Agency (EMA) has officially accepted Evive Ryzneuta™ for the treatment of chemotherapy-induced neutropenia (CIN).
-
Domestic and foreign pharmaceutical companies have accelerated their innovation, and huge investment has become the norm
Time of Update: 2021-11-04
On October 18, Ipsen and Accent Therapeutics also announced that they have reached an exclusive global cooperation agreement to jointly advance the research, development, manufacturing and commercialization of drugs targeting the RNA-modified protein METL3 .
-
The tens of billions of ophthalmic drugs market Chengdu pharmaceutical companies' second-class new drugs strike
Time of Update: 2021-11-04
According to data from Mi Nei. com, in recent years, Kanghong Pharmaceutical's market share in ophthalmic drugs has continued to rise, and it has been promoted to TOP2 .
-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
Target EGFR×HER3!
Time of Update: 2021-11-04
ArticleMedicine GuanlanAccording to information published on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the BL-B01D1 for injection declared by Bailey Pharmaceutical has obtained a clinical implied license and is intended to be developed for the treatment of locally advanced or metastatic epithelial tumors .
-
A quick look at the news about foreign "medicine" this month
Time of Update: 2021-11-04
A quick overview of key foreign drug news this month: Roche T drug was approved to treat early lung cancer; FDA approved Merck K drug combined with chemotherapy for first-line treatment of cervical cancer; AstraZeneca Imfinzi combined with tremelimumab to treat liver cancer phase 3 clinical end; Eli Lilly Verzenio was awarded FDA approved the treatment of early breast cancer .
-
Under the general trend of innovation in the pharmaceutical industry, the approval of domestically produced innovative drugs is showing a blowout trend
Time of Update: 2021-11-04
According to data, the approval of domestically-made innovative drugs for the market this year is showing a blowout trend .
According to the current trend, the industry believes that in the next 2-3 years, there will be more than 20 PD-1 products on the global market, while 15 PD-1 products on the domestic market will become increasingly fierce .
-
30 provinces determine the time for the fifth batch of national procurement bids
Time of Update: 2021-11-04
The following is a summary of the 30 provinces that have announced their bid execution dates as follows:JilinJilinOn October 20, the Jilin Provincial Medical Insurance Bureau published the "Notice on the Implementation of the Fifth Batch of National Organizations and the Results of the Selection of Jilin Province for Centralized Procurement of Drugs in the "Eight Provinces and Two Districts"", announcing that it will officially implement the round of this round from October 20, 2021.
-
Can Bojian ASO's new drug fail to perform Alzheimer's disease drug "miracle" again
Time of Update: 2021-11-04
Recently, Biogen announced the results of a failed clinical trial in a positive and optimistic manner: the phase III VALOR study of Tofersen, an investigational drug for the treatment of ALS (amyotrophic lateral sclerosis) targeting SOD1, did not meet the primary endpoint.
-
Pharmaceutical stocks are showing signs of rebound, and many sub-sectors are optimistic
Time of Update: 2021-11-04
Implemented in the direction of allocation: focus on the rhythm of core assets, focus on external demand and focus on global international competitive advantages (CDMO, the global new crown vaccine & therapeutic drug industry chain, injection exports, and some internationalized equipment); the sharp decline is looking for early pessimistic expectations Suppressed health consumption upgrade (consumer medical care, medical services, etc.
-
Aosaikang's subsidiary Polymyxin E Methanesulfonate Sodium for Injection Obtained Drug Registration Approval
Time of Update: 2021-11-04
Polymyxin E sodium methanesulfonate for injection has become the last line of defense for multi-drug-resistant Gram-negative bacterial infections that are ineffective in the treatment of antibiotics such as β-lactams, aminoglycosides or quinolones .
-
Microchip announced that the world's first PPAR full agonist sitaglipta sodium for the treatment of type 2 diabetes has been approved for marketing in China
Time of Update: 2021-11-04
The successful R&D and approval of sitaglipta sodium not only demonstrates Microchip's innovative spirit and beliefs, but also demonstrates the strength of China's innovative drug R&D and clinical research on diabetes, and breaks the long-term dilemma that it is difficult to treat diabetes insulin resistance.
-
Xiao Ling, director of Jinling Pharmaceutical, resigns
Time of Update: 2021-11-04
On October 20, Jinling Pharmaceutical issued an announcement stating that the board of directors had recently received a resignation report from director Ms.
-
Teyi Pharmaceutical's compound sulfamethoxazole tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-11-04
Compound sulfamethoxazole tablets are sulfa antibacterial drugs, which are a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP).
The drug is mainly used to prevent or treat infections caused by sensitive strains .
-
Technology "empowers" Chinese medicine, making the modernization of Chinese medicine a viable path
Time of Update: 2021-11-04
Enterprises should develop modern Chinese medicine scientific research and industrial production technology through technological innovation to promote the high-quality development of the Chinese medicine industry .
-
National procurement has landed, the two provinces do not engage in "one size fits all", and the allocation ratio of unselected varieties in Shanghai is about 20%
Time of Update: 2021-11-04
At present, 25 provinces and cities have clarified the official implementation time of the fifth batch of national procurement: Xinjiang: September 15, 2021 Tianjin: September 20, 2021 Hunan: October
-
The listing of 27 domestically-made innovative drugs involves Hengrui, Baekje, Hausen...
Time of Update: 2021-11-04
In addition to Hengrui, other pharmaceutical companies are also increasing their investment in innovative research and development .
At the Fifth China Pharmaceutical Supervision Science Conference, Academician Liu Changxiao believes that in the research and development of new drugs, the influencing factors of the synergy between society, the environment, and the government cannot be ignored .
-
The development of traditional Chinese medicine in China attracts attention, the academic journal "Nature" focuses on outstanding achievements
Time of Update: 2021-11-04
Focus on the special issue report with the theme of "In-depth understanding of acupuncture and traditional Chinese medicine", focusing on the use of modern technology by the Shanghai University of Traditional Chinese Medicine research team to study acupuncture and traditional Chinese medicine therapies for the treatment of chronic pain, asthma, liver fibrosis and improve the standard of Chinese medicine At the same time, the Focus Special Issue introduced the school’s achievements in international exchanges and expansion of international influence .
-
Injecting naloxone Zimhi receives FDA approval to treat opioid overdose
Time of Update: 2021-11-04
The reason may be that the US Food and Drug Administration (FDA) approved the company's injection of naloxone Zimhi for the treatment of opioid overdose .
In November 2019, Adamis's New Drug Application (NDA) for its Zimhi high-dose naloxone injection product was rejected by the FDA .
